Abstract
567P Furmonertinib in combination with bevacizumab and intrathecal chemotherapy as later-line re-challenge treatment in EGFR –mutated NSCLC patients with leptomeningeal metastasis after third-generation EGFR-TKIs treatment failure
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have